Aethlon Medical prices $4.5 million public offering at $0.90 per share

SAN DIEGO - Aethlon Medical, Inc. (NASDAQ:AEMD) announced Thursday the pricing of a public offering to raise approximately $4.5 million in gross proceeds. The medical therapeutic company, with a current market capitalization of $3.52 million, is offering 5,000,000 shares of common stock (or pre-funded warrants) and warrants to purchase up to 5,000,000 additional shares at a combined price of $0.90 per share. According to InvestingPro data, the stock has experienced significant volatility, with an 80% decline year-to-date.

The warrants will have an exercise price of $0.90 per share, will be immediately exercisable upon issuance, and will expire five years after issuance. The offering is expected to close on or about Friday, subject to customary closing conditions. InvestingPro analysis shows the company maintains a healthy current ratio of 2.49, with liquid assets exceeding short-term obligations.

Maxim Group LLC is serving as the exclusive placement agent for the offering.

Aethlon intends to use the net proceeds for general corporate purposes, including clinical trial expenses, research and development, capital expenditures, and working capital, according to the company’s statement.

The offering is being conducted pursuant to a registration statement on Form S-1 that was declared effective by the Securities and Exchange Commission on September 4.

Aethlon Medical focuses on developing products to treat cancer and life-threatening infectious diseases. The company is advancing its Hemopurifier platform, which is designed to selectively remove pathogenic targets from biological fluids. While the company holds more cash than debt on its balance sheet, InvestingPro data indicates it is not currently profitable, with analysts projecting continued losses this year. For deeper insights into Aethlon’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

The information in this article is based on a press release statement from Aethlon Medical.

In other recent news, Aethlon Medical Inc. reported a significant reduction in operating expenses during its Q1 2025 earnings call. The company emphasized cost-saving measures and a strategic focus on its Australian oncology trial. Aethlon also highlighted advancements in its Hemopurifier technology and preclinical research in long COVID. Despite these developments, the company noted a minor dip in its stock price. Analysts have not provided new upgrades or downgrades at this time. Aethlon remains optimistic about its innovation pipeline and market potential, focusing on strategic areas to drive future growth. These recent developments reflect the company’s ongoing efforts to enhance its financial health and position in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.